PolTREG

Nobel Lecture by Dr. Mateusz Gliwiński, MD, PhD – PolTREG S.A. & Gdański Uniwersytet Medyczny (Medical University of Gdańsk).

The second lecture in the Nobel Lectures series at the Faculty of Chemistry, Uniwersytet im. Adama Mickiewicza w Poznaniu, was delivered by Dr. Mateusz Gliwiński, MD, PhD (PolTREG S.A. & Gdański Uniwersytet Medyczny (Medical University of Gdańsk), who shared his scientific and expert knowledge in the field of immunology.

Lecture topic: “Tregs – how not to be (eaten) by your own immune system”. In summary, the lecture explained how regulatory T cells (Tregs) maintain immune system balance and why they are crucial in preventing autoimmunity. It also highlighted the therapeutic potential of Tregs, including their application in autoimmune diseases and type 1 diabetes.

PolTREG S.A. is a biotechnology company focused on the development of innovative cell therapies based on regulatory T lymphocytes (Tregs) for the treatment of autoimmune diseases.

Pictures source: https://chemia.amu.edu.pl/wydzial/aktualnosci-wydzialowe/relacja-z-drugiego-wykladu-noblowskiego-dr.-n.-med.-mateusza-gliwinskiego

PolTREG S.A. on Strefa Inwestorów - Praktycznie o inwestowaniu

During the Skuteczny Inwestor 2025 conference, Paweł Biedrzycki interviewed Prof. Piotr Trzonkowski and Mariusz Jablonski - a conversation particularly relevant for investors analyzing the biotech sector.

Key topics discussed:
- the significance of this year’s Nobel Prize in Medicine and its impact on the development of TREG cell–based therapies, the core technology behind PolTREG’s approach to treating autoimmune diseases
- the preclinical and clinical advancement of PolTREG’s programs, with clearly defined indications and a global market of unmet medical needs
- regulatory strategy (FDA), financing, grants, and partnering potential

PolTREG S.A. is an example of a Polish biotech company where science, intellectual property, and business strategy are aligned and scalable.

If you are analyzing biotech/medtech companies and looking for projects with growth potential, this interview is well worth watching.

Interview link (in Polish):

Tegoroczna Nagroda Nobla z medycyny zwiększyła zainteresowanie projektami spółki PolTREG Tegoroczna Nagroda Nobla w dziedzinie medycyny została przyznana za odkrycia dotyczące komórek regulatorowych Treg, które PolTREG wykorzystuje w rozwijaniu t...

We are proud to welcome Dr. Adrian Bot, a renowned biopharmaceutical founder and scientist, who joins Immuthera’s Board of Directors and will also serve as Scientific Advisor to PolTREG S.A.

Dr. Adrian Bot has joined Immuthera to support the company with his unique experience in the commercialization of groundbreaking cell therapies.

Immuthera — PolTREG’s wholly owned U.S. subsidiary — is advancing breakthrough T regulatory (Treg) cell-based therapies to transform the treatment of autoimmune diseases.

“PolTREG is a global leader in the development of T-regulatory cell products with over 12 years of clinical experience in more than 100 patients. This data set in autoimmune disease patients is a unique strength in our rapidly evolving field of cell therapies. I am very excited to help Immuthera and PolTREG advance and commercialize transformative therapies based on engineered Tregs, for patients in need. We are traversing an inflexion point for the field, and I have high confidence in the leadership team under Dr. Piotr Trzonkowski as they are well positioned for a U.S. expansion.”— comments Dr. Adrian Bot.

Dr. Bot brings 27 years of experience in the U.S. biopharmaceutical industry:
• Founding CSO and EVP of R&D at Capstan Therapeutics, where he helped secure $165M in financing before its $2.1B acquisition by AbbVie (2025).
• Leadership roles at Kite Pharma, where he contributed to the success of Yescarta® and Tecartus®, landmark CAR-T cell therapies, prior to the company’s $11.9B acquisition by Gilead (2017).

" Dr. Bot is a seasoned, accomplished, and well respected leader in the evolving field of cell and gene therapies. He has demonstrated on two separate occasions, the ability to lead innovations in Cell therapy from R&D, to clinical translation, to acquisition, in the fields of ex vivo-engineered CAR-T and In-Vivo CAR-T. We share the vision that T regulatory cells, reinforced by the recent Nobel Prize awarded for their discovery, represent the next frontier in cell therapies for patients with autoimmunity and other disease indications. Dr. Bot’s experience and innovative scientific and business approach will be invaluable on our journey to ultimately commercialize Tregulatory cell therapies. We look forward to Dr. Bot’s input and guidance as we bring our therapies into the US and continue to develop next-generation Treg and Treg-based therapies," says Prof. Piotr Trzonkowski, founder and CEO of Poltreg S.A.

PolTREG continues to expand its U.S. presence through Immuthera, its collaboration with Kinexum Services LLC on FDA strategy, and an exclusive partnership with Antion Biosciences to develop multi-edited, allogeneic CAR-Treg therapies.

Zachęcamy do lektury 👇